Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma.

This study examined the association between 17p allelic loss and p53 gene mutation in a series of 16 esophageal adenocarcinomas arising on a background of Barrett's esophagus. Two highly polymorphic dinucleotide repeat polymorphisms mapping to 17p13 were analyzed to assess the frequency of 17p allelic loss in these tumors. Mutations in the p53 gene were detected by direct DNA sequencing. Ninety-four % (15 of 16) of samples were informative at one or both polymorphic loci. Allelic loss at one or both loci was detected in 80% (12 of 15) of samples. Mutations were detected in 69% (11 of 16) esophageal adenocarcinomas, and there was a close association between 17p allelic loss and p53 gene mutation (P = 0.00879; Fisher's Exact Test). The tumors that were analyzed demonstrated a specific p53 mutation spectrum, with G:C to A:T base transitions at CpG dinucleotides accounting for 80% (8 of 10) of single-base substitutions. In three cases, the same p53 mutation was detected in both high-grade dysplasia and adjacent tumor. These results indicate that p53 gene alterations contribute to the development of esophageal adenocarcinoma and precede the development of invasive carcinoma in patients with Barrett's esophagus.

[1]  S. Tornaletti,et al.  Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. , 1995, Oncogene.

[2]  G. Thomas,et al.  TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. , 1994, Gastroenterology.

[3]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[4]  Carissa A. Sanchez,et al.  p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. , 1994, Gastroenterology.

[5]  Cécile Fizames,et al.  The 1993–94 Généthon human genetic linkage map , 1994, Nature Genetics.

[6]  N. Shepherd,et al.  Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. , 1994, Gut.

[7]  Carissa A. Sanchez,et al.  17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. , 1994, Cancer research.

[8]  D. Beer,et al.  Intestinal differentiation and p53 gene alterations in barrett's esophagus and esophageal adenocarcinoma , 1994, International journal of cancer.

[9]  D. Amadori,et al.  Base transitions are the most frequent genetic changes at P53 in gastric cancer. , 1993, Cancer research.

[10]  Patricia L. Blount,et al.  Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. McDaniel,et al.  Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. , 1993, Cancer research.

[12]  J. Fléjou,et al.  Overexpression of p53 protein in Barrett's syndrome with malignant transformation. , 1993, Journal of clinical pathology.

[13]  Patricia L. Blount,et al.  Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. , 1992, Cancer research.

[14]  Leland Hartwell,et al.  Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells , 1992, Cell.

[15]  A. Cameron,et al.  Barrett's esophagus: age, prevalence, and extent of columnar epithelium. , 1992, Gastroenterology.

[16]  S. Meltzer,et al.  Barretts carcinoma in a 25-year-old man with point mutation of the p53 tumor suppressor gene. , 1992, International journal of oncology.

[17]  A. J. Levine.  The p53 tumor-suppressor gene. , 1992, The New England journal of medicine.

[18]  Patricia L. Blount,et al.  Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Blount,et al.  Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. , 1992, Gastroenterology.

[20]  K. Kinzler,et al.  Carcinogens leave fingerprints , 1992, Nature.

[21]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[22]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[23]  A. Puisieux,et al.  Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. , 1991, Cancer research.

[24]  Carissa A. Sanchez,et al.  17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. , 1991, Cancer research.

[25]  M. Skolnick,et al.  Dinucleotide repeat polymorphism at the D17S513 locus. , 1991, Nucleic acids research.

[26]  J. Roth,et al.  p53 gene mutations in Barrett's epithelium and esophageal cancer. , 1991, Cancer research.

[27]  M. Rudnicki,et al.  Simplified mammalian DNA isolation procedure. , 1991, Nucleic acids research.

[28]  R. Metcalf,et al.  Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. , 1991, Cancer research.

[29]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[30]  B. Vogelstein,et al.  Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. A. Metcalf,et al.  Mutational hot spot in the p53 gene in human hepatocellular carcinomas , 1991, Nature.

[32]  J. Fraumeni,et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.

[33]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[34]  J. Minna,et al.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. , 1990, Oncogene.

[35]  C. McConkey,et al.  Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. , 1990, British Journal of Cancer.

[36]  S. McClave,et al.  Incomplete intestinal metaplasia in the diagnosis of columnar lined esophagus (Barrett's esophagus). , 1989, American Journal of Clinical Pathology.

[37]  Y. Nakamura,et al.  Allelotype of colorectal carcinomas. , 1989, Science.

[38]  P. Chumakov,et al.  A variation in the structure of the protein-coding region of the human p53 gene. , 1988, Gene.

[39]  B. Glickman,et al.  Sequence specificity of mutations induced by benzo[a]pyrene-7,8-diol-9,10-epoxide at endogenousaprt gene in CHO cells , 1988, Somatic cell and molecular genetics.

[40]  T. Mack,et al.  Tobacco, alcohol, diet, occupation, and carcinoma of the esophagus. , 1988, Cancer research.

[41]  S. Hecht,et al.  Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. , 1988, Carcinogenesis.

[42]  W G Doos,et al.  Adenocarcinoma and Barrett's esophagus. An overrated risk? , 1984, Gastroenterology.

[43]  T. P. Dryja,et al.  Expression of recessive alleles by chromosomal mechanisms in retinoblastoma , 1983, Nature.

[44]  C. S. Yang,et al.  Research on esophageal cancer in China: a review. , 1980, Cancer research.

[45]  Philip J. Farabaugh,et al.  Molecular basis of base substitution hotspots in Escherichia coli , 1978, Nature.

[46]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[47]  W. Thilly.  Mutational spectrometry in animal toxicity testing. , 1990, Annual review of pharmacology and toxicology.

[48]  B. Reid,et al.  Progression to cancer in Barrett's esophagus is associated with genomic instability. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[49]  J. Miller.  Mutational specificity in bacteria. , 1983, Annual review of genetics.